U.S. Biosimilars Market Revenue Outlook (2024–2032)

Free

in USD Million

U.S. Biosimilars Market: Rapid Growth and Long-Term Forecast (2024–2032)

Published by MMR Statistics Reserch Team, November 2025

The U.S. Biosimilars Market continued to advance rapidly in 2024, driven by expanding therapeutic adoption, increasing biologic patent expirations, and strong regulatory support for interchangeable biosimilars. Market revenue was recorded at USD 11,940.74 million in 2024 and is projected to reach USD 29,868.93 million by 2032, reflecting the country’s accelerated shift toward cost-efficient biologic alternatives. Growth is further supported by expanding oncology and immunology portfolios, broader payer acceptance, and improved formulary access across hospital and retail channels. As leading manufacturers scale production, invest in next-generation biosimilar pipelines, and strengthen distribution partnerships, the U.S. maintains its position as one of the fastest-growing global biosimilars markets. Increasing competition, strategic pricing, and continued FDA approvals will continue to shape market performance throughout the forecast period.

OTHER STATISTICS ON TOPIC

Biosimilars

More statistics on Biosimilars

Download

Information

Unit

in USD Million

Region

United States

Time Period

2024-2032

Source Name

Maximize Market Research Pvt. Ltd

Source Link

http://www.maximizemarketresearch.com

Publisher Name

Maximize Market Research Pvt. Ltd

Publisher Link

http://www.maximizemarketresearch.com

Related reports

Market Research Reports on Biosimilars

Explore published research tied to this statistic's topic. Open the featured edition or jump into another region without leaving the page.

Open featured report

Subscriptions

Stay ahead of Biosimilars with tailored access

Sample free-tier statistics or unlock premium coverage for this topic with team-friendly usage rights.

Discover

Try free-tier statistics before committing to a plan.

Start for Free

Professional

Unlock premium coverage across this topic with analyst support.

Select Plan

Contact our team

Need a bespoke deep-dive on Biosimilars?

Tell us about your KPIs and coverage priorities. We can tailor a briefing, share methodology notes, or build a custom dataset that complements the reports and statistics you are browsing.

Talk with an analyst